• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

By: Cullinan Therapeutics, Inc. via GlobeNewswire
May 24, 2024 at 08:00 AM EDT

CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024.

The fireside chat is scheduled for Wednesday, May 29, 2024 at 11:30am Eastern Time. A webcast will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/.

About Cullinan Therapeutics  

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about our Company at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.   

Contacts: 
Investor Relations 
Chad Messer 
+1 203.464.8900 
cmesser@cullinantx.com 

Media 
Rose Weldon 
+1 215.801.7644 
rweldon@cullinantx.com 


Primary Logo

More News

View More
News headline image
Palantir Stock Finds Its Footing—and a Path to Global Growth ↗
Today 8:20 EST
Via MarketBeat
Tickers PLTR
News headline image
The $100 Million Tell: Following Smart Money Into DoorDash ↗
Today 7:37 EST
Via MarketBeat
Tickers CRTO DASH
News headline image
Wall Street’s Sleeping Giant: Is Amazon About to Wake Up? ↗
December 02, 2025
Via MarketBeat
Tickers AAPL AMZN GOOGL
News headline image
Checkmate in the Cloud: ServiceNow's Shopping Spree ↗
December 02, 2025
Via MarketBeat
Tickers MOVE NOW
News headline image
The Contrarian Case for MSTR Amid MSCI Delisting Debacle ↗
December 02, 2025
Via MarketBeat
Tickers MSTR

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.42
+0.00 (0.00%)
AAPL  286.19
+0.00 (0.00%)
AMD  215.24
+0.00 (0.00%)
BAC  53.19
+0.00 (0.00%)
GOOG  316.02
+0.00 (0.00%)
META  647.10
+0.00 (0.00%)
MSFT  490.00
+0.00 (0.00%)
NVDA  181.46
+0.00 (0.00%)
ORCL  201.10
+0.00 (0.00%)
TSLA  429.24
+0.00 (0.00%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap